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tenofovir disoproxil fumarate 
induces peripheral neuropathy 
and alters inflammation and 
mitochondrial biogenesis in the 
brains of mice
Jerel Adam fields1,5*, Mary K. Swinton1, Aliyah carson1, Benchawanna Soontornniyomkij3, 
charmaine Lindsay3, May Madi Han3, Katie frizzi3, Shrey Sambhwani1, Anne Murphy  4, 
Cristian L. Achim3, Ronald J. ellis  2 & Nigel A. calcutt3,5
Mounting evidence suggests that antiretroviral therapy (ART) drugs may contribute to the prevalence 
of HIV-associated neurological dysfunction. The HIV envelope glycoprotein (gp120) is neurotoxic and 
has been linked to alterations in mitochondrial function and increased inflammatory gene expression, 
which are common neuropathological findings in HIV+ cases on ART with neurological disorders. 
Tenofovir disproxil fumarate (TDF) has been shown to affect neurogenesis in brains of mice and 
mitochondria in neurons. In this study, we hypothesized that TDF contributes to neurotoxicity by 
modulating mitochondrial biogenesis and inflammatory pathways. TDF administered to wild-type (wt) 
and GFAP-gp120 transgenic (tg) mice caused peripheral neuropathy, as indicated by nerve conduction 
slowing and thermal hyperalgesia. Conversely TDF protected gp120-tg mice from cognitive dysfunction. 
In the brains of wt and gp120-tg mice, TDF decreased expression of mitochondrial transcription factor 
A (TFAM). However, double immunolabelling revealed that TFAM was reduced in neurons and increased 
in astroglia in the hippocampi of TDF-treated wt and gp120-tg mice. TDF also increased expression of 
GFAP and decreased expression of IBA1 in the wt and gp120-tg mice. TDF increased tumor necrosis 
factor (TNF) α in wt mice. However, TDF reduced interleukin (IL) 1β and tnfα mRNA in gp120-tg 
mouse brains. Primary human astroglia were exposed to increasing doses of TDF for 24 hours and then 
analyzed for mitochondrial alterations and inflammatory gene expression. In astroglia, TDF caused 
a dose-dependent increase in oxygen consumption rate, extracellular acidification rate and spare 
respiratory capacity, changes consistent with increased metabolism. TDF also reduced IL-1β-mediated 
increases in IL-1β and tnfα mRNA. These data demonstrate that TDF causes peripheral neuropathy in 
mice and alterations in inflammatory signaling and mitochondrial activity in the brain.
Combination antiretroviral therapy (ART) has extended the life expectancy of people with HIV (PWH)1–3. 
However, comorbidities such as peripheral neuropathy and cognitive dysfunction persist in people in whom 
ART has suppressed viral loads1,4–6. As the population of PWH ages and people of older age are more often newly 
infected compared to early on in the epidemic7, there is a need to better understand how ART drugs and low-level 
viral replication or protein production may contribute to comorbidities in PWH.
Despite the success of ART, neurological disorders of the peripheral nervous system (PNS) and central nerv-
ous system (CNS) affect approximately 20–50% of PWH1,8,9. In the pre-ART era HIV associated neurocognitive 
disorders (HAND) affected as high as 50% of PWH10–12. However, the severity of HAND has been reduced with 
only 2–3% of PWH being afflicted with HIV-associated dementia10. The majority of HAND cases are diagnosed 
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with asymptomatic neurocognitive impairment (ANI) or minor neurocognitive disorder (MND)10. The high 
prevalence of the more subtle categories of HAND is at first glance confounding since PWH on ART often 
have low to undetectable viral loads. Studies have shown that low-level HIV protein expression may persist in 
PWH on ART13,14, but mounting evidence suggest that ART drugs may also underlie some of the neurological 
dysfunction15–20.
Nucleoside reverse transcriptase inhibitors (NRTI) have been linked to mitochondrial dysfunction since soon 
after their implementation21,22. AZT and d-drugs were associated with mitochondrial pathology in peripheral 
neurons21,22. Mitochondrial DNA (mtDNA), a key component of mitochondrial biogenesis and gene expression, 
may be damaged by ART drugs21,23. Initial studies determined that NRTI drugs altered the function of human 
mtDNA polymerase γ and damaged mtDNA21,24. Reductions in metabolites such as acylcarnitine in the brain 
suggested that mitochondrial dysfunction may persist in people on ART25,26. Newer ART regimens do not show 
the same level of toxicity as older drugs. However, symptoms of neuronal dysfunction persist in patients starting 
on newer drugs. The NRTI, tenofovir disoproxil fumarate (TDF), a highly prevalent component of modern ART 
regimens, has been to shown to affect mitochondria in cultured neurons20. In vivo mouse studies have shown that 
TDF can affect neurogenesis in the brain, which could be involved in the persistence of HAND16. TDF is part of 
a combination of ART drugs taken as preventative prophylaxis by people at high risk for contracting HIV. It is 
important to understand if TDF is toxic to mitochondria in the CNS in vivo.
Mitochondrial biogenesis is increasingly seen as a therapeutic target in both peripheral neuropathy and CNS 
neurodegenerative diseases27. To maintain healthy mitochondria, under a tightly regulated process, cells generate 
new mitochondria, while degrading damaged mitochondria (mitophagy)28. Mitochondrial biogenesis requires 
activation of transcription factors peroxisome proliferator-activated receptor α coactivator 1-α (PGC-1α) and 
mitochondrial transcription factor A, (TFAM) when energy (adenosine triphosphate [ATP]) is low. Alterations in 
levels of PGC-1α and TFAM are implicated in several neurodegenerative diseases including Alzheimer’s Disease 
(AD), Huntington’s disease (HD), and Parkinson’s disease (PD)29–32. HIV infection33, ART34, and AD are also 
associated with reduced levels mtDNA in the brain35. Remarkably, enhancing mitochondrial biogenesis32,36 is 
neuroprotective in rodent models of AD, HD, and PD. We recently reported that overall levels of PGC-1α and 
TFAM in the frontal cortex of HAND brains are reduced, particularly in neurons37. Interestingly, astroglia have 
increased levels of TFAM in these same brains. Increased astroglial TFAM may be due to activation by inflamma-
tory cytokines, though the precise mechanism of this shift in HAND brains is not well understood37.
Although viral replication is low in PWH on ART, there is some evidence that HIV protein production persists 
in both the periphery and in the CNS13,14. Astrogliosis and microgliosis remain a hallmark of HIV infection in the 
ART era38,39. Increased levels of inflammatory gene expression are still observed in postmortem brain specimens 
from people that were on ART40. Though there are no perfect models to study HIV infection and much less HIV 
infection during the ART era, the GFAP-gp120 transgenic (gp120-tg) mouse model reproduces much of the neu-
ropathology observed in postmortem brains from HAND cases41,42. The gp120 tg model shows increased astro-
gliosis and microgliosis and reduced integrity of neuronal processes and synapses, mirroring reports in HAND 
brains from the ART era17,41,43. More detailed neuropathological hallmarks of HAND have also been observed in 
the gp120-tg mouse model including alterations in autophagy, and mitochondrial dynamics and morphology41,42. 
The gp120 tg mouse model may provide a solid platform to investigate the combined effects of some HIV protein 
expression in the context of ART exposure.
In the present study, wild-type (wt) and gp120 tg mice were utilized to understand the effects of TDF and 
gp120 on PNS function and on mitochondrial biogenesis transcription factors PGC-1α and TFAM and mito-
chondrial fission protein, dynamin-like protein (DNM1L). We also performed neuropathological analyses to 
understand how alterations in mitochondrial biogenesis are associated with neurodegeneration, gliosis and 
inflammation. Finally, we corroborated our findings using in vitro models for human astroglia and microglia. 
The data herein provide new details on how TDF alters mitochondrial biogenesis and inflammatory signaling in 
in vivo and in vitro settings.
Methods
Mouse studies. For these studies, an animal model of HIV-protein mediated neurotoxicity, tg mice express-
ing high levels of gp120 under the control of the glial fibrillary acidic protein (GFAP) promoter, were used as 
previously described41,44. These mice develop neurodegeneration accompanied by astrogliosis, microgliosis, and 
memory deficits in the water maze test44. They have also been reported to develop indices of peripheral neurop-
athy after 12–15 months of age, onset of which can be accelerated by treatment with the reverse transcriptase 
inhibitor didanosine45. Wt and gp120-tg mice were aged 7–8 months at the start of the study. TDF was purchased 
from MedChemExpress LLC and dissolved in sterile H2O at 6 mg/ml. Mice were treated with vehicle or TDF 
(50 mg/kg) daily by oral gavage for 4 weeks. Mice underwent assays for sensorimotor coordination, learning and 
memory (repeated accelerating rotarod test46,47), paw thermal sensation and large fiber motor nerve conduction 
velocity (MNCV), exactly as described in detail elsewhere48 with assays performed both before and after the 
treatment regimen. After physiological and behavioral testing was complete, mice were euthanized and brains 
were excised 3 days after last administration of TDF, sagittally sectioned and the left hemibrain was snap frozen 
for biochemical and RNA analyses and the right hemibrain was immersion immersion fixed in 4% paraformal-
dehyde for one week.
Rotarod. Each mouse was placed on a rotating rod (1.25 inch diameter: Rotarod, Stoelting) facing the experi-
menter. Rotation was activated, and the rate of rotation increased gradually from the starting speed of 4 rotations 
per minute (RPM) to a maximum of 40 RPM within 120 seconds. The time at which the mouse fell from the rod 
was recorded by a sensor.
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Motor nerve conduction velocity. To evaluate the function of large myelinated motor nerve fibers, motor 
nerve conduction velocity (MNCV) was measured as described in detail elsewhere48. Briefly, mice anesthetized 
with 4% isoflurane in oxygen and four platinum-tipped sub-dermal needle electrodes (Grass Technologies) con-
nected to a PowerLab stimulator (AD Instruments). The grounding electrode was inserted into skin at the back 
of the neck. One of the recording electrodes was inserted into the interosseous muscle between the second and 
third toes, and the other into the muscle between the third and fourth toes. The PowerLab stimulator was set to 
deliver a 200-mV, 50-μsec-duration square wave stimulus every 2 seconds. The stimulating electrode was first 
inserted into the ankle at the Achilles tendon and the resulting electromyogram (EMG) containing the M wave 
(M Achilles wave) recorded. The stimulating electrode was moved to the sciatic notch and the EMG M wave at the 
notch (M notch wave) recorded. This process was repeated three times while alternating the stimulating electrode 
between the Achilles tendon and the sciatic notch. The leg was then stretched and the superficial distance between 
the Achilles tendon and the sciatic notch measured with a caliper. To calculate MNCV in m/s, the difference 
between M Achilles and M notch was calculated for all three repeats and the median value divided by the distance 
between the Achilles tendon and the sciatic notch.
Heat sensitivity testing. The function of small sensory fibers in paw skin was measured as described in 
detail elsewhere48 using a Hargearves test device (UARD) to record time to paw withdrawal from a heat stimulus 
that increased at a rate of 1 °C/sec from a starting surface temperature of 30 °C. Mice were placed on the glass sur-
face of the device inside restraint chambers and allowed an acclimation period of 15 minutes. After acclimation, 
the heat source was moved directly under the plantar surface of the left hind paw and activated. A movement 
sensor detected paw withdrawal from the glass surface, stopped the heating and recorded the time between onset 
of heating and paw withdrawal. Heating automatically stopped after 20 seconds (50 °C) to prevent paw damage. 
Measurements were not made when mice were grooming, urinating or rearing, only when the paws remained 
flat on the glass surface. Measurements were made on both hind paws and repeated four times. The median of 
the four measurements for each hind paw was calculated and thermal response latency of the mouse calculated 
by averaging the median measurements of left and right hind paws. The thermal response latency (seconds) was 
converted to response temperature using a calibration curve that was constructed from multiple daily measure-
ments of the heating rate of the glass surface.
Immunoblot. Mouse brains were homogenized and fractionated using a buffer that facilitates separation of 
the membrane and cytosolic fractions (1.0 mmol/L HEPES (Gibco, cat. no. 15630–080), 5.0 mmol/L benzamidine, 
2.0 mmol/L 2-mercaptoethanol (Gibco, cat. no. 21985), 3.0 mmol/L EDTA (Omni pur, cat. no. 4005), 0.5 mmol/L 
magnesium sulfate, 0.05% sodium azide; final pH 8.8) as described in a previous publication37. In brief, as pre-
viously described42, tissues from brain samples (0.1 g) were homogenized in 0.7 ml of fractionation buffer con-
taining phosphatase and protease inhibitor cocktails (Calbiochem, cat. no. 524624 and 539131). Samples were 
precleared by centrifugation at 5000 × g for 5 min at room temperature. Supernatants were retained as the whole 
lysate and stored at −80 until use.
As previously described37, after determination of the protein content of all samples by bicinchoninic acid assay 
(Thermo Fisher Scientific, cat. no. 23225) and denaturing in lamellae sample buffer (Bio Rad, cat. no. 1610747), 
whole lysates were loaded (10 μg total protein/lane) on 4–15% Criterion TGX stain free gels (Bio Rad, cat. no. 
5678085) and electrophoresed in Tris/Glycine/SDS running buffer (Bio Rad, cat. no. 161–0772) and transferred 
onto LF PVDF membrane with Bio Rad transfer stacks and transfer buffer (Bio Rad, cat. no 1704275) using Bio 
Rad Trans Blot Turbo transfer system. After the transfer, total protein was imaged using Bio Rad ChemiDoc 
imager under the stain free blot setting for normalization purposes. The membranes were then blocked in 1% 
casein in tris-buffered saline (TBS) (Bio Rad, cat. no. 1610782) for 1 h. Membranes were incubated overnight at 
4 °C with primary antibodies diluted in blocking buffer. All blots were then washed in PBST, and then incubated 
with species-specific IgG conjugated to HRP (American Qualex, cat. no. A102P5) diluted 1:5000 in PBST and vis-
ualized with SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific, cat. no. 34096). 
Images were obtained, and semi-quantitative analysis was performed with the ChemiDoc gel imaging system and 
Quantity One software (Bio-Rad).
Immunohistochemistry and double immunolabeling of brain sections. As previously described37, 
free-floating 40 μm thick vibratome sections of mouse brains were washed with phosphate buffered saline with 
tween 20 (PBST) 3 times, pre-treated for 20 minutes in PBS 3% H2O2/1%TritonX, and blocked with 2.5% horse 
serum (Vector Laboratories) for 1 hour at room temperature. Sections were incubated at 4 C overnight with the 
primary antibodies, TFAM (Invitrogen, cat. no. PA5-23776), GFAP (Sigma, cat. No. G3893), and IBA1 (Wako, cat. 
no. 019–19741). Sections were then incubated in secondary antibody, Immpress HRP Anti-rabbit IgG (Vector, 
cat. no. MP-7401) or Impress HRP Anti-mouse IgG (Vector, cat. No. MP-7402) for 30 minutes, followed by 
NovaRED Peroxidase (HRP) Substrate made with NovaRED Peroxidase (HRP) Substrate Kit as per manufactur-
er’s instructions (Vector, cat. no. SK-4800). Control experiments consisted of incubation with secondary antibody 
only. Tissues were mounted on Superfrost plus slides and coverslipped with cytoseal. Immunostained sections 
were imaged with a digital Olympus microscope and assessment of levels of TFAM, GFAP, and IBA1 immunore-
activity was performed utilizing the Image- Pro Plus program (Media Cybernetics, Silver Spring, MD). For each 
case a total of three sections (10 images per section) were analyzed in order to estimate the average number of 
immunolabelled cells per unit area (mm2) and the average intensity of the immunostaining (corrected optical 
density). Background levels were obtained in tissue sections immunostained in the absence of primary antibody. 
Therefore: corrected optical density = optical density − background. GFAP and IBA1 positive cells were quanti-
fied in the hippocampi using Image J analysis software.
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Double immune-labeling was performed in the same manner as immunohistochemistry staining up until 
secondary antibody incubation. Sections were stained with primary antibodies, TFAM, GFAP, MAP2 and IBA1 
overnight at 4 degrees C, after which they were washed three times with PBS and incubated in secondary fluo-
rescent antibodies for 30 min. After incubating in secondary antibodies, tissues were washed with PBST three 
times and then incubated in DAPI diluted 1:10,000 for 15 min. After 15 min, DAPI was removed and tissues were 
washed three times with PBST before mounting on coverslips and cover slipping with vectashield.
RNA isolation and real-time reverse transcription polymerase chain reaction (RT2PCR). RNA 
was isolated from the frontal cortex of mouse brains using the RNeasy Lipid Tissue Kit (Qiagen, cat. No. 74804). 
Brain tissue was homogenized in Qiazol followed by the addition of chloroform. Homogenates were centrifuged 
at 12,000 g for 15 min. The aqueous layer was removed, and RNA was isolated from this layer according to man-
ufacturers’ instructions.
As previously described37, RNA was reverse transcribed into cDNA with a High capacity cDNA Reverse 
Transcription Kit (Life technologies, cat. no. 4358813) as per manufacturer’s instructions. Gene expression was 
determined using rt2PCR TaqMan gene expression assays performed using the StepOnePlus sequence-detection 
system (Life Technologies), using primers specific to IL-1β and TNFα. ACTB was used as a normalization con-
trol. A master mix was made using 2x Fast advanced master mix (Thermofisher, cat. no. 4444557), 20x primers, 
and water. 8ul of master mix and 2ul of cDNA was added to each reaction well (The reactions were carried out at 
48 °C for 30 min and 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min). Samples were 
analyzed in duplicate. Fold changes were calculated using the comparative CT method.
Cell culture. This study was approved by the University of California San Diego Human Research Protections 
Program. All research was performed in adherence to the relevant guidelines and regulations. As previously 
described37, astroglia were isolated from fetal human brain tissue from elective terminated pregnancy between 
12 and 16 weeks of gestation, acquired from Advanced Bioscience Resources. Donors gave written informed con-
sent for research-use of the cells and tissue. Tissue was fragmented and mechanically dissociated using a scalpel 
and washed 3 times with HBSS holding media (Gibco, cat. no.14175–095) with 1 mM Glutamax (Gibco, cat. no. 
35050–061), 20ug/mL Gentamicin (Gibco, cat. no. 15710–064) and 5 mM HEPES (Gibco, cat. no. 15630–080). 
The tissue was homogenized with the addition of 15 mL of 0.25% trypsin EDTA (Gibco, cat. no. 25200–056) for 
5 min in a 37 °C incubator. After 5 min, 1 mL of a trypsin inhibitor (Roche, cat. no. 10109) and 24 mL of DMEM 
media (Gibco, cat. no. 11960–044) with human serum (Corning, cat. no. 35–060-cl) was added. The mixture was 
then centrifuged for 5 min at 4 °C to pellet the cells. Supernatant was removed and discarded, and the cells were 
resuspended in 5 ml of DMEM media and strained with a 70 μM strainer (Falcon, cat. no. 352350). The cell sus-
pension was underlaid with 7 ml of a solution of filtered 8% BSA in PBS and cells were centrifuged at 1 × 104 rpm 
at 4 °C for 10 min. The supernatant was removed, and the cells were resuspended in DMEM media with human 
serum. Astroglia were plated at a density of 1 × 107/T75 flask and cultured as adherent monolayers. After 1 week, 
the astroglia DMEM media with human serum was replaced with DMEM media with 10% fetal bovine serum 
(FBS) (Gibco, cat. no. 16000044) and 1% penicillin/ streptomycin (P/S) (Corning, cat. no. 30–001-CI-1). Every 3 
days, a half media exchange was performed on each cell type.
A vial of human microglial cell 3 (HMC3) was purchased from (CRL-3304). HMC3 and cultured in EMEM 
with 10% FBS and penicillin/streptomycin as per ATCC instructions. Cells were split every 5 days using 
trypsin-EDTA.
Antibodies. GFAP (Sigma Aldrich, cat# G3893), TFAM (Invitrogen, cat# PA5-23776) and MAP2 (Santa Cruz 
Biotechnologies, cat# sc-32791), PGC-1α (Abcam, cat#. ab54481), IBA1 (Wako, cat# 019-19741).
Seahorse assay. As previously described37, astroglia were split into a seahorse plate at 3 × 104 cells/well and 
treated with Vehicle or TDF for 24 h. On the following day, cultures were incubated in a non-CO2 incubator at 
37 °C to equilibrate for approximately 30 minutes prior to assay. Baseline measurements of ECAR were taken 
prior to addition of oligomycin (2 μM), followed by a titrated concentration of FCCP, and then rotenone (500 nM) 
together with antimycin (1 μM) (Sigma-Aldrich, cat no. A8674). After each addition of mitochondrial inhibitor, 
three readings were taken before injection of the subsequent inhibitor. ECAR was automatically calculated and 
recorded by the Seahorse XFe96 software. Rates were calculated by the Seahorse analyzer, reported as log of H+ 
production rate and then normalized to control for presentation. Samples were run in biological replicates of five 
in two independent experiments.
Ethical approval for studies. This study was approved by the University of California San Diego Human 
Research Protections Program. All experiments described were approved by the animal subjects committee at 
the University of California, San Diego (UCSD), and were performed according to NIH recommendations for 
animal use.
Results
indices of peripheral neuropathy are induced by tenofovir disproxil fumarate but cognitive per-
formance is protected. WT and gp120-tg mice were indistinguishable at onset of the study, as indices of 
peripheral neuropathy do not develop in this strain until around 1 year of age44. TDF induced significant MNCV 
slowing and paw thermal hyperalgesia in both wt and gp120-tg mice compared to pre-treatment values (Table 1). 
We also measured rotarod performance, both as an indicator of sensorimotor function when measured in iso-
lation and also as an index of learning and memory when measured iteratively46,47. All groups showed similar 
performance at baseline whereas at study end, WT mice treated with vehicle or TDF spent significantly more 
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time on the rotarod, indicative of learning and memory (Table 1). Vehicle-treated gp120-tg mice did not improve 
performance over time, whereas significant improvement was restored in gp120-tg mice treated with TDF.
PGC-1α, TFAM and DNM1L protein levels are altered in brain lysates from wt and gp120-tg 
mice administered Tenofovir disproxil fumarate. To determine the relative abundance of key tran-
scription factors involved in mitochondrial biogenesis in mouse brains, whole lysates were assayed for PGC-1α, 
TFAM, and DNM1L levels by immunoblot. The band corresponding to PGC-1α appeared as a single band in 
the expected 100 kDa range, with the most intense and large band appearing in the gp120-tg mice treated with 
TDF (Fig. 1a). The raw immunoblot images are included (Supplementary Fig. 1). The signal for TFAM appeared 
at the 30 kDa mark in a similar pattern, with the strongest band for TFAM detected in the wt mice (Fig. 1a). 
The band for DNM1L appeared at 90 kDa with the strongest band in the wt mice, weakest in the gp120tg mice 
(Fig. 1a). Densitometry analyses were performed on each band by normalizing to the total protein transferred to 
the PVDF membrane for that lane. The densitometry for PGC-1α was significantly (**p < 0.01) increased in TDF 
treated, gp120-tg and in gp120-tg + TDF compared to wt (Fig. 1b). Densitometry analyses showed the signal for 
TFAM was significantly (**p < 0.01) reduced in TDF treated, gp120-tg and in gp120-tg + TDF compared to wt 
(Fig. 1c). Densitometry analyses for DNM1L bands confirmed a significant reduction in gp120-tg mice compared 
to wt (Fig. 1d). However, DNM1L in gp120-tg mice treated with TDF was not significantly different than wt or 
wt + TDF (Fig. 1d).
TFAM and MAP2 signals are reduced in hippocampi from wt and gp120-tg mice administered 
Tenofovir disproxil fumarate. In order to determine the neuronal integrity in the brains of wt and 
gp120-tg mice treated with TDF, we double immunolabeled vibratome sections with TFAM (red) and MAP2 
(green). In brains from vehicle treated wt mice the signal for TFAM was present throughout the soma and pro-
cesses of hippocampal neurons (CA1 region) (Fig. 2a). However, in vehicle-treated gp120-tg or wt and gp120-tg 
mice treated with TDF, the TFAM signal was more punctate throughout the soma and processes of neurons 
(Fig. 2a). MAP2 signal was as expected in wt mice, being noted throughout neuronal soma and processes, but in 
vehicle-treated gp120-tg and gp120-tg mice treated with TDF the MAP2 signal was greatly diminished suggesting 
loss of neuronal integrity (Fig. 2a). Yellow signal, indicating colocalization of MAP2 with TFAM, was noticeably 
reduced in all three groups, in vehicle-treated gp120-tg or wt and gp120-tg mice treated with TDF, compared 
to the brains of vehicle-treated wt mice (Fig. 2a). These observations were supported by quantification of pixel 
intensity in the confocal images. In mouse brains from vehicle-treated gp120-tg or wt and gp120-tg mice treated 
with TDF, the signal intensity for TFAM was significantly decreased compared to wt mouse brains (Fig. 2b). In 
mouse brains from vehicle-treated gp120-tg or wt and gp120-tg mice treated with TDF, the MAP2 pixel intensity 
was significantly decreased (Fig. 2c). In mouse brains from vehicle treated in vehicle-treated gp120-tg or wt and 
gp120-tg mice treated with TDF, the percent of TFAM signal colocalizing with MAP2 signal was significantly 
decreased (Fig. 2d).
GFAP and GFAP/TFAM colocalization is increased in GP120 mouse hippocampi. Astrogliosis can 
be identified by immunostaining astroglia for glial fibrillary acidic protein (GFAP). Due to the elongation of 
astroglia processes, astrogliosis will present with an increase in staining for GFAP compared to the inactivated 
state. To determine the state of astroglia in the brains of transgenic gp120-tg mice treated with TDF, vibratome 
sections were immuonstained for GFAP with the addition of primary antibodies specific for GFAP and second-
ary antibodies conjugated to HRP that were reacted with NovaRed. In the hippocampus, as expected there was 
increased staining for GFAP in GP120 mouse brains compared to the wild type (Fig. 3a). The GFAP signal was 
also increased in wt treated with TDF compared to vehicle treated. However, there was no additive or synergistic 
increase in the gp120-tg mice (Fig. 3a). These observations are consistent with optical density measurements, 
which show a significant increase in GFAP density in GP120 mouse hippocampi compared to wild type (Fig. 3b). 
In the wt group, treatment with TDF led to a significant increase in GFAP optical density compared to the vehicle 
treated group, but this TDF-mediated increase was not seen in the GP120-tg group (Fig. 3b). To determine if 
TDF or gp120 affect proliferation of GFAP+ astroglia, GFAP+ cells were counted in the hippocampi using Image 
J. The number of GFAP+ cells in gp120-tg and gp120 + TDF mice was significantly increased compared to wt 
and to wt +TDF (Supplementary Fig. 3a). When analyzed by t test, the number of GFAP+ cells in wt + TDF was 
significnantly increased compared to wt mice.
Group N M:F
Body Weight (g) Rotarod Latency (sec) MNCV (m/sec)
Heat Response Threshold 
(°C)
Onset Final Onset Final Onset Final Onset Final
WT + V 8 1:7 28.5 ± 1.9 27.8 ± 2.0 11.1 ± 1.9 18.9 ± 3.5a 43.2 ± 1.4 41.1 ± 2.9 38.8 ± 0.6 38.0 ± 0.7
WT + T 5 2:3 31.4 ± 3.7 30.8 ± 4.2 8.1 ± 0.7 17.6 ± 3.4a 44.1 ± 0.7 28.8 ± 5.2a 39.8 ± 1.0 36.0 ± 0.5a
gp120-tg + V 9 6:3 31.4 ± 2.5 30.2 ± 2.5 10.4 ± 1.1 11.4 ± 3.4 42.1 ± 1.8 38.9 ± 3.7 40.9 ± 1.0 39.8 ± 1.3
gp120-tg + T 12 8:4 29.6 ± 1.9 28.7 ± 2.1 9.7 ± 1.1 18.2 ± 1.8c 43.7 ± 2.0 32.7 ± 3.2c 40.2 ± 0.6 37.7 ± 0.7b
Table 1. Peripheral neuropathy caused by tenofovir (T). Mice were 7–8 months old at the start of the study 
and tenofovir was given daily (50 mg/kg po) for 4 weeks. Data are group mean ± SEM. a,b,cp < 0.05, p < 0.01 and 
p < 0.001 vs group onset values by paired t test.
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Astroglia play a critical role in neuronal homeostasis and energy provision. To investigate if astroglial acti-
vation in GP120-tg mice is associated with alterations in transcription factor A, mitochondrial (TFAM), vibra-
tome sections were double immunolabeled for TFAM (red) and GFAP (green). The signal for TFAM was 
noticeably decreased in hippocampi of gp120 tg, TDF-treated wt and TDF-treated gp120-tg mice compared to 
vehicle-treated wt mice (Fig. 3c). As expected, signal for GFAP was increased in gp120-tg mice whether treated 
with vehicle or TDF (Fig. 3c). GFAP signal was also more prominent in the TDF treated wt mice compared 
to vehicle treated wt mice (Fig. 3c). The merged images of GFAP and TFAM staining show an increase in yel-
low signal, indicating increased colocalization of TFAM with GFAP signal in all three groups compared to 
vehicle-treated wt mice (Fig. 3c). The pixel intensity for GFAP was significantly increased in gp120-tg mice and 
in TDF-treated mice compared to vehicle treated mice in both GP120 and wild type groups (Fig. 3d). Although 
TFAM signal decreased in tenofovir treated groups compared to vehicle treated groups, % colocalization of 
GFAP-TFAM increased significantly (Fig. 3e). An increase in colocalization of TFAM and GFAP concurrent with 
an increase in GFAP staining suggests a greater consumption of energy by astroglia concurrent with astrogliosis 
in the GP120 mice and mice treated with TDF.
IBA1 is decreased in hippocampus of mice treated with TDF. Ionized calcium binding adaptor mol-
ecule 1 (IBA1) is a calcium binding protein specific to microglia/macrophage that has actin-bundling activity and 
participates in phagocytosis and membrane ruffling in activated microglia (Ohasawa et al., 2004). Expression of 
IBA1 is upregulated in activated microglia in several brain diseases. To determine if microglia are activated in 
TDF-treated mice and in gp120-tg with and without treatment with TDF, we immunostained vibratome sections 
for IBA1 using NovaRed and preformed intensity/area analysis. IBA1 staining was increased in gp120-tg mouse 
brains compared to wild type brains in matched treatment samples (Fig. 4a). Treatment with TDF decreased the 
signal for IBA1 in both wt and gp120-tg mouse hippocampal regions (Fig. 4a). Quantification of IBA1 signal 
intensity/area revealed a significant increase in IBA1 in gp120-tg mouse brains compared to wt (Fig. 4b). IBA1 
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Figure 1. PGC-1α protein levels are increased and TFAM and DNM1L protein levels are decreased in brain 
lysates from wt and gp120-tg mice administered Tenofovir disproxil fumarate. (a) Immunoblot for PGC-1α, 
TFAM, and DNM1L using whole lysates from hippocampal region. (b—d) Densitometry for quantification of 
PGC-1α, and TFAM, and DNM1L normalized to total protein levels. Significance (p < 0.05) was determined by 
two-way ANOVA (wt, n = 8; wt + TDF, n = 5; gp120-tg, n = 7; gp120-tg, n = 7).
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signal in hippocampi of TDF-treated wt mice was significantly reduced compared to vehicle treated wt mice 
(Fig. 4b). Similarly, IBA1 signal in the TDF-treated gp120-tg mice was significantly reduced compared to IBA1 
in the gp120-tg group (Fig. 4b). To determine if TDF or gp120 affect proliferation of microglia, IBA1+ cells were 
counted in the hippocampi. The number of IBA1+ cells in gp120-tg mice was significantly increased compared 
to wt and to wt + TDF and gp120-tg TDF (Supplementary Fig. 3b).
To confirm the findings from chromagen immunostaining, vibratome sections of mouse brain were immunos-
tained for IBA1, labeled with fluorescent-conjugated secondary antibodies and visualized using confocal micros-
copy in the hippocampi (Fig. 4c). The results mirrored the results from the NovaRed with a few exceptions. IBA1 
signal was strongest in the vehicle-treated gp120-tg group, but TDF reduced this signal (Fig. 4d). Treatment 
with TDF also decreased the signal of IBA1 in both the wt mouse group, and, unlike the NovaRed staining, 
this decrease reached significance (Fig. 4d). These data suggest that IBA1 is upregulated in GP120-tg mouse 
brains and that this upregulation was blocked by treatment with TDF. The upregulation of IBA1 could suggest an 
increase in activated microglia in GP120-tg mice, which can be inhibited with TDF administration.
TDF reduces levels of mRNA transcripts for inflammatory cytokines in gp120-tg mice. To 
determine relative levels of IL-1β and TNFα mRNA expression in the brains of wt and gp120-tg mice, total RNA 
was isolated from mouse brains from each group. IL-1β mRNA levels were increased 2.5-fold (**p < 0.01) in 
brains of gp120-tg mice compared to wt mice (A). However, in gp120-tg mice treated with TDF, levels of IL-1β 
mRNA were not significantly different than wt or wt treated with TDF (Fig. 5a). In wt mice, TDF increased 
TNF-α mRNA by 50% compared to wt mice treated with vehicle (**p < 0.05 by t-test) (Fig. 5b). TNFα mRNA 
levels were increased 2-fold (*p < 0.05) in brains of gp120-tg mice compared to wt mice (Fig. 5b). However, in 
gp120-tg mice treated with TDF, levels of TNFα mRNA were not significantly different than wt or wt treated with 
TDF (Fig. 5b). These data suggest a novel mechanism through which TDF simultaneously affects mitochondrial 
function and gliosis while reducing inflammatory signaling in the brain.
Figure 2. TFAM and MAP2 signals are reduced in hippocampi from wt and gp120-tg mice administered 
Tenofovir disproxil fumarate. (a) Vibratome sections of mouse brains were double immunolabelled with 
antibodies for TFAM and MAP2. (b) MAP2 pixel intensity was quantified using Image J software. (d) The 
percent of the TFAM signal (red) colocalizing with the MAP2 signal (green) was assessed using Image J and the 
SQUASSH plug-in (white arrows indicate points of colocalization). Significance (p < 0.05) was determined by 
two-way ANOVA (wt, n = 3; wt + TDF, n = 4; gp120-tg, n = 4; gp120-tg, n = 4).
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TDF increases mitochondrial activity in human astroglial cultures. The effects of ART drugs on 
astrglial mitochondrial function is an unexplored area of research. To determine how TDF affects mitochondrial 
activity in human astroglia, we exposed primary human astroglia to increasing doses of TDF (20 ng/ml, 200 ng/
ml and 2 ug/ml) and measured oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
using the Seahorse XF96 platform. Spare respiratory capacity (SRC) was calculated by subtracting the minimal 
OCR after oligomycin treatment from the maximum OCR after FCCP treatment. TDF caused a dose dependent 
increase in astroglial OCR with the highest dose increasing OCR by 50% compared to vehicle treatment (Fig. 6a). 
TDF also caused a dose-dependent increase in SRC with the two highest TDF doses being ~40% higher than 
vehicle treatment alone (Fig. 6b). The highest dose of TDF caused an increase in ECAR that was significantly 
higher than vehicle or the lower two doses (Fig. 6c). These data are consistent with the in vivo findings that show 
TDF increases TFAM expression in astroglia indicating increased mitochondrial activity. Data were analyzed 
using one-way ANOVA and Tukey’s multiple comparisons. Data are representative of at least three independent 
experiments in human primary astroglia from at least two independent genetic backgrounds.
TDF blocks inflammatory gene expression in astroglia. To understand how TDF affects inflamma-
tory gene expression, astroglia were treated with gp120 (100 ng/ml) or IL-1β (20 ng/ml) with or without TDF 
(200 ng/ml). RNA was isolated and analyzed by real-time (rt2) pcr for fold change of IL-1β and TNFα mRNA 
transcripts. TDF and gp120 alone had little effect on levels of IL-1β or TNFα mRNA. However, IL-1β, as expected 
caused a robust increase in IL-1β mRNA levels, but co-treatment with TDF reduced this by 50% (***p < 0.001) 
Figure 3. Tenofovir disproxil fumarate increases GFAP expression, reduces TFAM expression, and 
increases TFAM colocalization with GFAP in hippocampi of wt and gp120tg mice. Vibratome sections were 
immunolabelled with antibody against GFAP and then double immunolabelled for TFAM and GFAP. (a) GFAP-
DAB immunostaining in hippocampi. (b) Quantification of GFAP corrected optical density. (c) TFAM (red) 
and GFAP (green) signal in hippocampi. (d–e) Quantified colocalization of TFAM and GFAP and colocalization 
of TFAM with GFAP (white arrows indicate points of colocalization). Analyzed with two-way ANOVA test (wt, 
n = 3; wt + TDF, n = 4; gp120-tg, n = 4; gp120-tg, n = 4).
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(Fig. 7a). The HIV protein gp120 also caused an increase in astroglial IL-1b as expected (Fig. 7a). Similarly, IL-1β 
significantly increased TNFα mRNA levels, but co-treatment with TDF reduced levels by 60% (Fig. 7b). These 
data suggest that TDF is blocking inflammatory signaling in astroglia, consistent with what was observed in the 
mouse brains. Data were analyzed using one-way ANOVA and Tukey’s multiple comparisons. Data are repre-
sentative of three independent experiments in one line of human primary astroglia. However, it is noteworthy 
that TDF did not reduce IL-1β or TNFα in a second culture of human primary astroglia of different genetic back-
ground, which responded similarly to IL-1β.
Tenofovir disoproxil fumarate does not reduce IL-1β -mediated increases in IL-1β and tnfα 
mRNA in a human microglial cell line (HMC3). To understand how TDF affects inflammatory gene 
expression in microglia, HMC3 cells were treated with gp120 (100 ng/ml) or IL-1β (20 ng/ml) with or without 
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Figure 4. Tenofovir disproxil fumarate reduces IBA-1 signal in hippocampi of wt and gp120tg mice. Vibratome 
sections were immunolabelled for IBA1. (a) IBA1-DAB immunostaining in hippocampi. (b) Quantification 
of IBA1 corrected optical density. (c) IBA1+ glia (red) signal in hippocampi and quantification of IBA pixel 
intensity (d). Analyzed with two-way ANOVA test (wt, n = 3; wt + TDF, n = 4; gp120-tg, n = 4; gp120-tg, n = 4).
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Figure 5. Tenofovir disoproxil fumarate reduces IL-1β and TNFα mRNA levels in gp120-tg brains. Total RNA 
was isolated from frontal cortex and analyzed by rt2PCR for IL-1β and TNFα mRNA levels. (a,b) Fold-change of 
IL-1β and TNFα mRNA compared to wt mice. Analyzed with two-way ANOVA test (wt, n = 3; wt + TDF, n = 3; 
gp120-tg, n = 3; gp120-tg, n = 3).
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TDF (200 ng/ml). RNA was isolated and analyzed by rt2PCR for fold change of IL-1β and TNFα mRNA tran-
scripts. TDF and gp120 alone had little effect on levels of IL-1β or TNFα mRNA. However, IL-1β as expected 
caused a robust increase in IL-1β and TNFα mRNA levels, but co-treatment with TDF had no effect on IL-1β 
levels (Fig. 8a) or TNFα levels (Fig. 8b). Data were analyzed using one-way ANOVA and Tukey’s multiple com-
parisons. Data are representative of at least three independent experiments.
Discussion
This study provides the first evidence for the ART drug, TDF, affecting peripheral nerve function and CNS 
inflammation and mitochondrial biogenesis in an in vivo setting. TDF treatment produced large fiber MNCV 
slowing and small fiber-mediated paw thermal hyperalgesia in both wt and gp120-tg mice and in the CNS led 
to robust reductions in overall levels of a transcription factor that is crucial to maintaining mitochondrial net-
works, TFAM. Upon further investigation, the reductions in TFAM were localized to neurons, while TFAM was 
increased in astroglial cells in TDF-treated and gp120-tg mice. TDF induced astrogliosis49 in the mouse brains 
and in human astroglial cells in culture along with increased mitochondrial function. Interestingly, TDF blocked 
inflammatory cytokine transcription in the gp120-tg mouse brains and in the human astroglial cells in culture 
and reduced microgliosis in the gp120-tg mice. These potentially neuroprotective actions coincided with pre-
vention of loss of hippocampal neurons in gp120-tg mice and protection of improved rotarod performance over 
time, an assay that can serve as an index of learning and memory46,47. This is consistent with clinical reports that 
initiating ART improved cognitive performance in cohort of individuals with HAND50,51. These findings suggest 
novel multiple complex activities of TDF in the CNS to alter mitochondrial biogenesis and inflammatory signal-
ing and activation in astroglia and microglia.
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Figure 6. TDF increases mitochondrial activity in human astroglial cultures Human astroglia were treated 
with increasing doses of Tenofovir for 24 hours and then analyzed for OCR and ECAR using the Seahorse XF96 
analyzer. (a) OCR in astroglia exposed to increasing doses of TDF. (b) Spare respiratory capacity was calculated 
by subtracting the basal OCR from the maximum OCR. (c) ECAR in astroglia exposed to increasing doses of 
TDF. Analyzed with one-way ANOVA test (n = 3/group).
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Figure 7. Tenofovir disoproxil fumarate reduces IL-1β -mediated increases in IL-1β and TNFα mRNA in 
human astroglia. Human astroglia were exposed to TDF (200 ng/ml), recombinant gp120 (100 ng/ml), or IL-1β 
(20 ng/ml) for 6 hours and then RNA was isolated. (a) Fold-change of TNFα mRNA normalized to ACTB 
mRNA. (b) Fold-change of IL-1β mRNA normalized to ACTB mRNA. Data were analyzed by two-way ANOVA 
(n = 3/group).
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Despite the persistently high prevalence of HIV-associated neurological disorders in PWH on suppressive 
ART, relatively few studies have investigated how modern ART drugs affect the peripheral and central nervous 
systems. A prior study reported that the dideoxynucleoside antiretroviral drug didanosine caused loss of small 
sensory intra-epidermal nerve fibers (IENF) when given to young gp120-tg mice that appeared to represent 
acceleration of a slowly developing distal degenerative sensory neuropathy45. However, while didanosine did not 
impact nerve structure, electrophysiology or sensory function in wt mice, we found TDF produced both marked 
large motor fiber NCV slowing and paw thermal hyperalgesia in both gp120-tg and wt mice. The 50 mg/kg/day 
dose of TDF we used was selected from prior pharmacokinetic and toxicity studies in mice16,52,53 that by allomet-
ric scaling54,55 equates to a human dose of 0.42 mg/kg/day or 29 mg/70 kg person, well within the clinical dose of 
300 mg/day. There are reports of pain and other manifestations of peripheral neuropathy in some patients treated 
with TDF56–58 that have been linked to mitochondrial toxicity20,59. Mitochondrial dysfunction is increasingly 
implicated in the pathogenesis of a variety of peripheral neuropathies60,61. However, separating HIV vs ART drug 
induced peripheral neuropathy has been a controversial undertaking in clinical research. Our finding that unlike 
didanosine45, TDF also produced peripheral neuropathy in wt mice may represent a model system for evaluating 
mechanisms of pure ART neurotoxicity.
A study of 15 ART drugs found variable levels of neurotoxicity, with TDF reducing both MAP2 immunostain-
ing in neuronal cultures and also the signal emanating from neurons after exposure to a mitochondrial potential 
sensitive dye20. Our data corroborate these findings in an in vivo setting by showing alterations in MAP2 signal 
and transcription factors that regulate mitochondrial biogenesis. In a study that utilized the SIV-infected pig 
tailed macaque, an ART cocktail including TDF caused accumulation of reactive oxygen species and neurotox-
icity, though these events were not linked directly to mitochondrial dysfunction62. The findings in this report are 
also consistent with a recent study that showed TDF reduces neurogenesis in the CNS of mice16. Xu et al. used a 
combination of ART drugs to determine the effects on neural precursor cells using in vivo and in vitro models. The 
authors concluded that ART, mainly driven by TDF, may exacerbate brain injuries and neurocognitive impair-
ment associated with HAND by affecting neurogenesis. The study by Xu et al. did not investigate mitochondrial 
activity or inflammatory signaling but does offer support for the premise that ART can affect CNS function16. The 
findings presented here do not explain how TDF protected performance on a rotarod over time as reported in 
these studies. TDF effects on neurons may be context dependent, affecting different pathways in a healthy brain 
versus HIV+ brain. As discussed below, these differential effects of TDF may also be related to the observations 
in this study showing effects that TDF has on astroglia, microglia, and inflammatory gene expression in the brain. 
Future studies are needed to better understand the impact of TDF on neuronal survival in hippocampi.
Several pharmacogenetic studies have provided indirect evidence for ART-associated mitochondrial dysfunc-
tion leading to neurotoxicity. A study of the Adult AIDS Clinical Trials Group (ACTG) uncovered an association 
between mitochondrial haplogroup T and NRTI-associated peripheral neuropathy5. A separate study reported 
that mitochondrial polymorphism 4918 G may confer increased risk for peripheral neuropathy in people on 
ART63. Polymorphisms in the P2X4R and CAMKK2 genes may be associated with HIV-SN, and increased TNFα 
expression64. These findings may provide further evidence that inflammatory processes can compromise mito-
chondrial function in neurons65. Moreover, chemokine receptors on cells enveloping cutaneous nerves may 
facilitate infiltration of immune cells in patients with HIV-SN66. Recent studies suggest that immunometabolic 
mechanisms in microglia and astroglia may play a similar role in HAND40,67,68. While TDF reduced inflammatory 
gene transcription in the mouse brain and in human astroglia, increased TFAM in astroglia may suggest similar 
increased metabolic function in this cell type. Hence, these studies show that mitochondrial biogenesis, or more 
specifically TFAM, may be a therapeutic target for ART and HIV-induced neurological disorders. The reduc-
tions in TFAM in neurons in TDF-treated and gp120-tg mice coincide with reduced MAP2 signal and increased 
TFAM in astroglia. However, data show that TDF and gp120 do not act on TFAM in a synergistic or additive 
manner, suggesting that a mechanism may be in place to prevent further down regulation of TFAM. The fact that 
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Figure 8. Tenofovir disoproxil fumarate does not reduce IL-1β -mediated increases in IL-1β and TNFα mRNA 
in a human microglial cell line (HMC3). HMC3 cells were exposed to TDF (200 ng/ml), recombinant gp120 
(100 ng/ml), or IL-1β (20 ng/ml) for 6 hours and then RNA was isolated. (a) Fold-change of TNFα mRNA 
normalized to ACTB mRNA. (b) Fold-change of IL-1β mRNA normalized to ACTB mRNA. Data were analyzed 
by two-way ANOVA (n = 3/group).
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PGC-1α was increased in the brain may indicate that TDF and gp120 interfere with TFAM pathway downstream 
of PGC-1α. The HIV protein gp120 has been shown to activate p38 kinase69, which can activate mitochondrial 
biogenesis70,71, possibly explaining the high levels PGC-1α in the gp120-tg mice. These studies also confirmed 
previous findings of reduced DNM1L41, which was partially reversed by TDF. While gp120-tg mice showed no 
indices of peripheral neuropathy, including first test rodarod performance, they did show a failure to improve 
rotarod performance upon repeated testing, suggestive of cognitive impairment in these mice that may be caused 
by mitochondrial alterations and inflammatory gene expression.
The question remains as to whether the effect of TDF on neuronal mitochondrial function is direct or 
mediated through activation of microglia and astroglia. Previous studies suggest that TDF can affect neurons 
directly16,72. Our data clearly show that TDF has robust effects on glial activation both in vivo and in vitro. These 
data are consistent with studies by Cohen et al. that showed ART can induce inflammatory gene expression and 
cellular senescence in astroglia and endothelial cells72,73. Therefore, we hypothesize that TDF affects neuronal 
mitochondrial function directly and also through activation of glia. Indirect effects on neuronal mitochondrial 
function through activation of astroglia are consistent with our recent finding in HAND brains that astroglial 
TFAM is increased and neuronal TFAM is decreased37. This may be explained by a mechanism in which activated 
astroglia sequester energy substrate that would otherwise be utilized by neurons74. Another possibility is that 
astroglia secrete neurotoxic molecules as has been found using in vitro models67,75. Understanding the signaling 
between neurons and astroglia in states of chronic inflammation will be important to determine the role of TDF 
on neuronal mitochondrial function. The effects of TDF on TFAM and DNM1L deserve further investigation in 
human samples and in vitro and in vivo models.
HIV and ART may affect the phenotype of astroglia and microglia. The current model of HIV-induced 
CNS injury involves infiltration of infected monocytes into the brain where they secrete virus, viral proteins 
and inflammatory cytokines76,77. The virus can infect perivascular macrophages which secrete more toxic mol-
ecules initiating a neurotoxic cascade involving activation of uninfected bystander microglia and astroglia78,79. 
Although controversial, some studies suggest that astroglia are infected by HIV and express viral proteins at a 
low level80–82. With the advent of ART, it is believed that the viral component of the neurotoxicity is reduced, but 
how ART affects microglia and astroglia is not well understood. Moreover, recent findings suggest that activ-
ity of microglia and astroglia place them within a spectrum of phenotypes ranging from pro-inflammatory to 
anti-inflammatory75,83,84. Microglia and astroglia assume varying phenotypes in response to specific types of brain 
injury85–87. Modulating these phenotypes is a potential therapeutic strategy for neurodegenerative diseases. This 
study suggests that TDF, and possibly other reverse transcriptase inhibitors, may modulate gene expression net-
works and activation states of microglia and astroglia. Consistent with our findings, Melchjorsen et al. found 
that tenofovir and zidovudine each affect inflammatory cytokine production in human monocytes, though in 
different manners with tenofovir altering inflammatory gene expression after stimulation with ligands for toll-like 
receptor88. The data presented here suggest a dynamic relationship between TDF and gliosis. In wt mice, TDF 
clearly activates astroglia and induces a significant increase in TNFα mRNA, both of which have been associated 
with HIV-infected brains that were exposed to ART40. The more unexpected finding was that TDF reduced the 
signal for IBA1 protein, numbers of IBA1+ cells and mRNA levels for TNFα and IL-1β in gp120-tg mice. These 
findings suggest that TDF effects on inflammatory signaling in the brain may be different in an inflamed envi-
ronment compared to steady state. However, these data may be consistent with a finding in postmortem brain 
specimens from HIV+ people on ART that showed regimens including TDF were associated with reduced Aβ 
plaque deposition in the brain17. The robust reduction of microglial activation by TDF in the gp120-tg mice may 
indeed indicate that in the context of HIV protein expression, TDF may steer astroglia and microglia toward a 
more anti-inflammatory phenotype, which could have implications for therapeutic strategies. This reduction 
in microglial activation and expression of inflammatory cytokines could partially explain the results presented 
here showing that TDF administration improves rotarod performance in the gp120-tg mice. Further studies are 
needed to determine the effect of TDF on microglial and astroglial function and phenotypic markers and the 
downstream effects on cognitive function in the context of neuroinflammation.
Since the gp120-tg model expresses gp120 from the GFAP promoter, the initial inflammatory signal in this 
model may be from a combination of inflammatory gene expression from astroglia stimulated by endogenous 
gp120 expression and in microglia stimulated by exogenous gp120 and cytokines from astroglia. Therefore, it is 
important to understand if TDF is blocking IL-1β and TNFα mRNA transcription in the astroglia or microglia to 
understand the observed in vivo inhibition. Further, it is important to understand if this finding may be translatable 
to human brain cells. While the human astroglial and microglial models are not without limitations, the findings 
that TDF reduced IL-1β-induced IL-1β and TNFα transcription in human astroglia are consistent with the findings 
in the mouse brains. However, TDF did not have this anti-inflammatory effect in another line of astroglia with 
different genetic background suggesting that TDF effects on inflammation may vary by individual or population 
due to genetic interactions. The fact that TDF did not have the same effect on the HMC3 cells suggests that in the 
mice, TDF is acting on the astroglial inflammatory gene expression and that is preventing activation of microglia. 
Differences in the experimental design between the in vivo and in vitro studies could account for the different effects 
of TDF on microglial cells. The mice were exposed to TDF for four weeks, compared to 24 hours in the in vitro 
experiments using human cells. Increasing doses of TDF were used to determine responses by glial cells. However, 
the highest dose used (2ug/ml) is likely not relevant to the human condition and the results should be considered in 
that context. This novel mechanism of TDF interactions with astroglial and microglial activation and gene expres-
sion may have implications for ART regimens affecting glial phenotype in people with neurological disorders.
The major limitations of this study include a relatively small sample size, use of only one ART drug, the use of 
in vitro models that are known to not exactly replicate the biology of brain cells in vivo and the use of the a mouse 
model that expresses one HIV protein from a promoter active only in astroglia. The issue of small sample size 
is somewhat offset by the robust differences in readouts from different levels of analysis, across different model 
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systems and species. These findings should be further investigated to better understand how TDF affects astroglia 
and the downstream effects on neuronal function. The gp120-tg mouse model for HIV-induced neurotoxicity 
is not ideal for modeling HIV infection of the brain, but it does present many of the neuropathological features 
found in postmortem HIV+ brain tissues41,42,44,89, along with some aspects of cognitive impairment (d’Hooge et al. 
1999; Maung et al. 2014) that were reflected in the failure to improve rotarod performance by these mice in the 
present study. This finding suggests that cognitive impairment manifests in this model by 9 months of age, coin-
ciding with loss of hippocampal neurons. In future studies, it will be important to determine the levels of PGC1α 
in neuron and glial cells. It will also be important in a future study to investigate TFAM alterations in microglial 
cells, as metabolic alterations occur in myeloid lineage cells during inflammatory processes. Moreover, more 
investigation of the effect of TDF on neuronal cells is needed to fully understand the implications of the findings 
presented here.
These findings identify peripheral and central neurotoxicity of TDF in wt and gp120-tg mice in conjunction 
with protection against loss of hippocampal neurons and impaired learning/memory. Novel functions of TDF in 
modulating inflammatory signaling and mitochondrial homeostasis in the brain were also identified. Also clear 
from this report is the role of astroglia in responding to ART drugs and the downstream effects on inflammatory 
signaling. Monitoring ART drugs effects on brain cells may lead to optimization of ART regimens and reduction 
of neuropsychiatric adverse events in PWH. Furthermore, astroglia may represent a promising target for reducing 
microgliosis and inflammatory gene expression.
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